Shots:

• Abbott has received the US FDA’s EUA for AdviseDx SARS-CoV-2 IgM lab-based serology test for use on the ARCHITECT and Alinity platforms
• Till now- Abbott has received EUA for its seven tests- including molecular tests- a rapid antigen test and- an IgG Ab test for COVID-19
• The IgM test demonstrated 99.56% specificity and 95.00% sensitivity for patients tested 15 days after symptom onset. The test will give a more complete picture of where patients are in their recovery
  
   ­ Ref: Abbott | Image: Abbott